Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines.
Allergy
; 76(1): 45-58, 2021 01.
Article
in En
| MEDLINE
| ID: mdl-32691892
Full text:
1
Database:
MEDLINE
Main subject:
Biological Products
/
Dermatitis, Atopic
Type of study:
Guideline
/
Systematic_reviews
Limits:
Adolescent
/
Adult
/
Child
/
Humans
Language:
En
Year:
2021
Type:
Article